Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T)
NCT03585517 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2023-01-19
Summary
Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor to Patients With CD123+ AML
Conditions
Interventions
- DRUG
-
IM23
T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor
Sponsors & Collaborators
-
Beijing Immunochina Medical Science & Technology Co., Ltd.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 3 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-07-21
- Primary Completion
- 2020-08-01
- Completion
- 2020-10-01
Countries
- China
Study Locations
More Related Trials
-
Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
NCT06125652 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
NCT04835519 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia
NCT04923919 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia
NCT04265963 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
NCT02541370 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies
NCT02937103 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Evaluate the Safety and Efficacy of CD33 CAR-T in Patients With R/R AML
NCT05473221 ·Status: UNKNOWN ·Phase: PHASE1
-
Donor-derived CAR-T Cells in the Treatment of AML Patients
NCT04766840 ·Status: UNKNOWN ·Phase: PHASE1
-
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
NCT05480501 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies
NCT05239689 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Safety and Efficacy Evaluation of IM19 CAR-T Cells
NCT03142646 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia
NCT05225831 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
NCT02935153 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
NCT06911710 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
CAR-T Cells in the Treatment of Malignant Hematological Tumors
NCT05619861 ·Status: UNKNOWN ·Phase: NA
-
Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL
NCT03271515 ·Status: UNKNOWN ·Phase: PHASE1
-
CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia
NCT07201727 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia
NCT04599543 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL
NCT02656147 ·Status: UNKNOWN ·Phase: PHASE1
-
Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia
NCT03672851 ·Status: TERMINATED ·Phase: PHASE1
-
Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5)
NCT04803929 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
NCT03896854 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia
NCT05023707 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After Transplantation
NCT04336501 ·Status: UNKNOWN ·Phase: NA
-
Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
NCT07109323 ·Status: RECRUITING ·Phase: PHASE1/PHASE2